Skip to main content

Anticoagulation Reversal — Drug-Class Hub

Andexanet alfa (Andexxa) has been withdrawn from the US market after the FDA concluded in December 2025 that its risks (notably excess thromboembolic events) outweigh its benefits; AstraZeneca ended US sales on December 22, 2025.[1][2] As a result, 4-factor PCC is now the primary reversal strategy for apixaban- and rivaroxaban-associated life-threatening bleeding; update institutional reversal algorithms accordingly. Idarucizumab (Praxbind) remains the standard for dabigatran reversal.

This article is the drug-class pharmacology hub: mechanism, dose, evidence and safety for each reversal agent (idarucizumab, 4F-PCC, vitamin K, protamine) along with the post-andexanet landscape and the emerging ciraparantag pipeline.

For adjacent topics see VTE prophylaxis and Perioperative antibiotic prophylaxis.

Quick Reference — Matching Reversal Agent to Anticoagulant​

Anticoagulant / scenarioReversal when indicatedAlternativeOnsetDuration
Warfarin (VKA), life-threatening bleeding4F-PCC + IV vitamin K 5–10 mg[26]FFP + IV vitamin KPCC ~10 min[4]; vit K 4–6 h IV[3]PCC ~8 h[4]; vit K sustained[3][6][16]
Dabigatran, life-threatening or uncontrolled bleeding or emergency surgery/urgent procedureIdarucizumab 5 g IVIf unavailable for life-threatening bleeding, aPCC 50 U/kg (maximum 4,000 units); for dabigatran-associated ICH when idarucizumab is unavailable, NCS/SCCM 2016 also suggests aPCC or 4F-PCC 50 U/kg< 5 min12–24 h[3][4][7][14][15]
Apixaban / Rivaroxaban / Edoxaban with life-threatening bleeding and suspected residual drug effectOff-label 4F-PCC 25–50 U/kg (andexanet withdrawn in US)[1][2][3][4]aPCC 50 U/kg[3]~10 min~8 h
FondaparinuxNo specific antidote; specialist-guided off-label rescue for life-threatening bleeding———
UFHProtamine 1 mg / 100 U of circulating heparin (no more than 50 mg over 10 min)—Within 5 minProtamine half-life ~7 min; rebound anticoagulation may occur 30 min to 18 h after reversal[21][22][23]
LMWH (enoxaparin)Protamine 1 mg / 1 mg if ≤ 8 h; 0.5 mg / 1 mg if > 8 h (may not be required at ≥ 12 h)Specialist-guided rescue if protamine cannot be usedPartial anti-Xa reversal; anti-IIa more completely reversedVariable[21][29]

1. Idarucizumab (Praxbind) — The Dabigatran-Specific Standard​

Idarucizumab is a humanized monoclonal antibody Fab fragment that binds dabigatran and its acylglucuronide metabolites with higher affinity than dabigatran has for thrombin, neutralizing its effect immediately. Idarucizumab alone showed no procoagulant effect in endogenous-thrombin-potential testing.[14]

Dose​

  • 5 g IV. Two consecutive 2.5 g / 50 mL vials, given as sequential infusions or bolus injections[14]
  • An additional 5 g may be considered if clinically relevant bleeding recurs with elevated coagulation parameters, or if a second emergency surgery or urgent procedure is required with elevated coagulation parameters; repeat-treatment safety and effectiveness are unestablished.[14]

Evidence — RE-VERSE AD​

Pollack 2017 NEJM prospective cohort (n = 503):[15]

  • Group A: uncontrolled bleeding (n = 301); Group B: urgent procedure (n = 202)[15]
  • Median maximum reversal 100% (dilute thrombin time or ecarin clotting time) in evaluable patients with prolonged baseline clotting times; complete reversal by dTT in 99%, aPTT 93%, ECT 82% per the label summary[14]
  • In group A, bleeding cessation was confirmed within 24 h in 134/203 assessable patients; the median was 2.5 h among those 134. In group B, hemostasis was normal in 184/197 (93.4%) patients who underwent a procedure, which started a median of 1.6 h after idarucizumab.[15]
  • 90-day thrombotic events: 6.3% in group A and 7.4% in group B; restart anticoagulation when medically appropriate, with timing driven by bleeding control and thrombotic risk[15]
  • The 503-patient RE-VERSE AD cohort identified no serious adverse safety signal.[15]

Guideline positioning​

  • 2023 ACC/AHA/ACCP/HRS AF. Recommends idarucizumab for life-threatening dabigatran bleeding[4]
  • AHA/ASA ICH 2022. Idarucizumab is reasonable for dabigatran-associated spontaneous ICH (Class 2a, B-NR).[16]
  • NCS/SCCM 2016. Strong recommendation for idarucizumab in dabigatran-associated ICH if dabigatran was taken within 3–5 half-lives without renal failure or renal insufficiency prolongs exposure beyond that period[7]

Special points​

  • Dabigatran can be restarted 24 h after idarucizumab; resume anticoagulation as soon as medically appropriate[14]
  • Contains sorbitol 4 g per 5 g dose; risk of serious reaction in hereditary fructose intolerance[14]
  • If idarucizumab is unavailable: aPCC or 4F-PCC 50 U/kg (maximum 4,000 units); evidence for either fallback is limited.[3][7]
  • Dabigatran is approximately 35% protein bound (65% unbound). Hemodialysis can remove it, but clinical data are limited and redistribution can occur; discuss with nephrology when needed, especially with renal impairment.[24]
  • Activated charcoal 50 g if ingestion within 2–4 h[3]
  • Coagulation parameters may re-elevate between 12–24 h due to drug redistribution; clinically significant recurrence was rare in RE-VERSE AD[15]

2. Four-Factor PCC (Kcentra / Beriplex) — The Versatile Workhorse​

4F-PCC contains coagulation factors II, VII, IX, and X plus proteins C and S from pooled human plasma. 4F-PCC is FDA-approved for urgent VKA reversal in adults with acute major bleeding or a need for urgent surgery or an invasive procedure.[25] For life-threatening oral FXa-inhibitor bleeding in patients with AF, ACC/AHA/ACCP/HRS recommends it as one reversal option.[4] For spontaneous FXa-inhibitor-associated ICH, AHA/ASA says it may be considered.[16] FXa-inhibitor use is off-label, and Andexxa is no longer sold in the US.[25][1]

A. Warfarin (VKA) reversal — INR-based dosing​

Pretreatment INRDose (units factor IX / kg)Max dose
2–< 425 U/kg2,500 units[25]
4–635 U/kg3,500 units[25]
> 650 U/kg5,000 units[25]

Source: product label.[3][25] Dose by actual body weight up to 100 kg; for heavier patients do not exceed the listed maximum. Repeat dosing has not been studied and is not recommended. Measure the INR near the time of dosing. Balfaxar (Octapharma), a second US 4F-PCC, uses the identical INR/weight table but is labeled for VKA reversal before urgent surgery/invasive procedures; it also contains heparin.[28]

Evidence:

  • INCH RCT (VKA-associated intracranial hemorrhage, n = 50 treated): 4F-PCC 30 IU/kg versus FFP 20 mL/kg: INR ≤ 1.2 within 3 h in 67% versus 9%; 13 deaths overall (FFP 8, five from hematoma expansion; PCC 5, none from expansion). The trial was terminated early for safety concerns and was too small to show a clinical-outcome benefit; FFP is a second-line option when PCC is unavailable, at the cost of large volume and slower correction[27]
  • Puchstein 2023 meta. 4F-PCC superior to 3F-PCC for INR normalization (OR 3.50)[17]
  • 4F-PCC contains about 25× the concentration of vitamin K-dependent factors versus plasma (25 U/mL versus 1 U/mL), allowing smaller volumes and faster infusion[3]

Co-administer vitamin K with 4F-PCC for urgent VKA reversal; for life-threatening bleeding, use 5–10 mg IV vitamin K.[26] PCC provides immediate but temporary factor replacement (about 8 h); vitamin K restores endogenous factor production. Without vitamin K, INR rebounds at 12–24 h, with hematoma re-expansion.[6][16]

B. FXa inhibitor reversal — the primary strategy post-andexanet​

  • FXa-inhibitor bleeding: off-label 4F-PCC has been given as fixed 2,000 U or 25–50 U/kg; the optimal dose is unestablished.[4] For FXa-associated intracranial hemorrhage specifically, the 2026 NCS/SCCM update conditionally favors 4F-PCC over andexanet for spontaneous ICH (moderate certainty) and traumatic ICH (very low certainty).[3][4][33]
  • Off-label for FXa inhibitors; supported by the ACC 2020 bleeding pathway and the AF guideline[3][4]
  • Mechanism: PCC does not reduce anti-FXa activity levels; it overwhelms the anticoagulant effect through factor supplementation, a non-specific "bypass" strategy that restores thrombin generation[16][18]

C. Dabigatran reversal (off-label) when idarucizumab unavailable​

4F-PCC or aPCC (FEIBA) 50 U/kg, maximum 4,000 units, may be used when idarucizumab is unavailable. For dabigatran-associated intracranial hemorrhage, NCS/SCCM recommends idarucizumab 5 g IV in two divided doses when dabigatran was taken within 3–5 half-lives without renal failure or when renal insufficiency prolongs exposure beyond that period ; if idarucizumab is unavailable or another direct thrombin inhibitor caused the hemorrhage, it suggests aPCC or 4F-PCC 50 U/kg when the inhibitor was taken within 3–5 half-lives without renal failure or renal insufficiency prolongs exposure beyond that period .[3][7]

Safety​

  • Boxed warning (Kcentra, Balfaxar): arterial and venous thromboembolic complications, including fatal events. Weigh reversal against the thrombotic risk of the underlying indication, and restart anticoagulation as soon as bleeding risk allows.[25][28]
  • In a meta-analysis of VKA-associated bleeding or urgent procedures, thromboembolic events did not differ significantly between 4F-PCC and FFP (4.2% versus 4.8%).[3][4][16]
  • Kcentra contains heparin and is contraindicated in known HIT, DIC, or severe reactions to its components.[25] Balfaxar also contains heparin and is contraindicated in heparin allergy or prior HIT, and in IgA deficiency with known anti-IgA antibodies.[28] Do not substitute another PCC by class name alone: composition and indications differ. Select an alternative with hematology/transfusion medicine.[25][28]
  • The labels state PCC may not be suitable after a thromboembolic event within the prior 3 months.[25][28] FEIBA (aPCC) has a boxed warning for embolic and thrombotic events and is contraindicated in DIC, acute thrombosis or embolism, or severe reactions to its components.[37]

3. Vitamin K (Phytonadione) — Specific VKA Antidote​

Restores intrinsic hepatic carboxylation of vitamin K-dependent clotting factors by overcoming warfarin's competitive inhibition.[3][19]

Routes and onset​

RouteOnsetFull correction
IV (urgent)INR reduction begins within 2 hGenerally within 24 h if hepatic function is normal and the dose is sufficient[19]
OralSlowerVariable; 5 mg PO and 1 mg IV produce similar INR effects at 24 h[19]
SubcutaneousUnpredictable absorptionNot recommended[3]

Dosing by scenario​

ScenarioDoseRoute
Life-threatening bleeding (with PCC)5–10 mgIV slow (no faster than 1 mg/min)[26][34]
Urgent VKA reversal when INR reduction is needed in 4–6 hVitamin K 2–10 mg, according to INR; use PCC when immediate reversal is requiredIV slow[36]
Urgent VKA reversal when 18–24 h for INR reduction is acceptableVitamin K 2–10 mg, according to INROral[36]
INR 4.5–10, no bleedingHold/adjust warfarin; no routine vitamin K (individualize for exceptional bleeding risk or procedural urgency)—
INR >10, no bleedingOral vitamin K; dose and follow-up INR per protocolOral

Sources: ACCP 9th edition (major bleeding: 4F-PCC preferred over plasma, plus vitamin K 5–10 mg slow IV; INR 4.5–10 without bleeding: routine vitamin K not suggested; INR > 10: oral vitamin K suggested), ACC 2020 expert consensus, AHA/ASA 2022.[26] The no-bleeding INR recommendations are distinct from emergency major-bleeding reversal.[26][3][5][6][19]

Key teaching points​

  • Vitamin K alone does not achieve rapid hemostasis. Must be combined with PCC for life-threatening bleeding.[6]
  • IV phytonadione can cause severe, sometimes fatal hypersensitivity even after dilution and slow infusion. Older guidance estimated anaphylactoid reactions at about 1 in 3,000 IV doses and advised dilution in at least 50 mL over 15–30 min; the current label warns that reactions can occur on first exposure and limits IV administration to no faster than 1 mg/min.[3][6][19][34]
  • Vitamin K reduces response to subsequent warfarin; if rapid re-anticoagulation is needed, heparin is usually preferred initially.[20]

4. Andexanet Alfa (Andexxa) — US Market Withdrawal​

Andexxa withdrawn from the US market. In December 2025 the FDA judged that the risks of andexanet alfa, including increased thromboembolic events, outweigh its benefits, and AstraZeneca ended US sales on December 22, 2025.[1][2] 4F-PCC is now the primary reversal strategy for FXa inhibitor-associated life-threatening bleeding in the US.

Mechanism​

Modified recombinant inactive form of human factor Xa that binds and sequesters apixaban and rivaroxaban. Also binds and inhibits tissue factor pathway inhibitor (TFPI), contributing to the prothrombotic signal. Elimination t½ about 5–7 h.[8][9]

Evidence​

ANNEXA-4 (NEJM 2019, n = 352). Single-arm cohort:[10]

  • Median anti-FXa activity fell 92% after the bolus for both apixaban and rivaroxaban; adjudicated excellent or good hemostasis 12 h after the end of the 2-hour infusion occurred in 204/249 efficacy-evaluable patients (82%).[10]
  • At 30 days, 49/352 patients (14%) had died and 34/352 (10%) had a thrombotic event. Of the 34 thrombotic events, 26 occurred before anticoagulation was restarted.[10]
  • Anti-FXa reduction did not predict hemostatic efficacy overall, but was modestly predictive in the intracranial-hemorrhage subgroup.[10]

ANNEXA-I (NEJM 2024, n = 530). First RCT, andexanet versus usual care (85.5% PCC) in FXa-associated acute ICH:[11]

  • Composite 12-hour hemostatic efficacy (hematoma expansion no more than 35%, NIHSS increase < 7, and no rescue therapy between 3 and 12 h) occurred in 150/224 (67.0%) with andexanet versus 121/228 (53.1%) with usual care (adjusted difference 13.4 percentage points; p = 0.003).[11]
  • Thrombotic events: 10.3% versus 5.6% (p = 0.048); ischemic stroke: 6.5% versus 1.5%[11]
  • No appreciable difference was detected in mRS or 30-day death. ANNEXA-I was not powered to establish whether better hematoma control improved functional outcome.[11]

Panos 2025 CCM retrospective (n = 1,096). In the full retrospective analysis, andexanet was associated with higher odds of excellent or good hemostasis (OR 1.60) and in-hospital thrombotic events (OR 1.91) than PCC; a prespecified sensitivity analysis excluding admission GCS < 7 found no hemostatic or thrombotic difference.[12]

Key safety liabilities that drove the withdrawal​

  • Boxed warning: arterial and venous thromboembolism, MI, ischemic stroke, cardiac arrest, sudden death[13]
  • In the later ANNEXA-4 label safety subset of apixaban- or rivaroxaban-treated patients, 45/419 (10.7%) had a thrombotic event (median first event 10 days).[13] In the FDA’s later 471-patient complete-follow-up ANNEXA-I safety analysis, 30-day thromboses were 35/239 (14.6%) with andexanet versus 16/232 (6.9%) with usual care, and thrombosis-related deaths were 6/239 (2.5%) versus 2/232 (0.9%); these denominators differ from the published trial analysis above.[1][35]
  • TFPI inhibition may create prothrombotic state beyond simple reversal
  • UFH unresponsiveness has occurred after andexanet, including failure of activated clotting time to prolong and serious thrombosis. The former US label advised against UFH after administration and recommended an alternative anticoagulant when needed.[13]
  • Anti-FXa activity re-elevates after the short half-life wears off[9]

Post-withdrawal implications​

  1. With andexanet unavailable in the US, off-label 4F-PCC regimens (25–50 U/kg or 2,000 U fixed) are options for apixaban / rivaroxaban / edoxaban-associated life-threatening bleeding[1][3][4]
  2. aPCC 50 U/kg is the alternative[3]
  3. Institutional pre-op checklists that list andexanet as backup need updating
  4. Keep the companion Antithrombotic therapy workflow and local formulary algorithm aligned

5. Protamine Sulfate — Heparin Reversal​

Basic protein derived from salmon sperm; binds heparin via nonspecific electrostatic interaction. Only clinically available UFH reversal agent.[21][22]

UFH reversal​

  • 1 mg protamine per 100 U of UFH, counting only heparin still circulating: the requirement falls quickly with time (about half the usual dose if given 30 min after the heparin dose)[22][23]
  • No more than 50 mg over 10 min, by very slow IV injection (about 5 mg/min); further dosing depends on the heparin remaining and coagulation results.[23]
  • Monitor with aPTT or anti-Xa

LMWH reversal​

Time since LMWHProtamine dose
Within 8 h (enoxaparin)1 mg per 1 mg enoxaparin; administer no more than 50 mg over 10 min. For therapeutic-dose dalteparin-associated intracranial hemorrhage within 3–5 LMWH half-lives, use 1 mg per 100 anti-Xa U (up to 50 mg).[7][23][29]
8–12 h0.5 mg per 1 mg enoxaparin[29]
> 12 hProtamine may not be required; individualize
Repeat dose when indicatedIf aPTT remains prolonged 2–4 h after the first infusion, repeat 0.5 mg per 1 mg enoxaparin; NCS/SCCM also suggests repeat dosing for persistent life-threatening intracranial bleeding or renal insufficiency after therapeutic-dose LMWH.[7][29]

Protamine fully reverses anti-IIa but only about 60% reverses anti-Xa activity. The enoxaparin label gives the 1 mg/1 mg (≤ 8 h) and 0.5 mg/1 mg (> 8 h) schedule and a second 0.5 mg/mg dose if the aPTT stays prolonged 2–4 h later.[21][29]

Fondaparinux​

Protamine has no effect. Older intracranial-hemorrhage guidance discusses rFVIIa as an off-label rescue option; clinical evidence is limited and thrombotic risk requires specialist assessment.[7]

FDA boxed warning​

Protamine Boxed Warning. Severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, pulmonary hypertension, anaphylaxis — particularly with high dose, overdose, rapid administration, or repeat exposure.[23]

Risk factors for severe protamine reactions​

  • Prior intolerance to protamine (contraindication); high dose or rapid administration[23]
  • Prior NPH or protamine-zinc insulin (common in diabetics). A frequently missed pre-op screening question
  • Fish allergy (label-listed possible risk factor)[23]
  • Previous vasectomy or male infertility (possible risk based on reported anti-protamine antibodies)[23]
  • Severe LV dysfunction; abnormal pulmonary hemodynamics[23]

The "excess protamine causes bleeding" paradox​

Excess protamine has its own anticoagulant effect and can worsen bleeding. Dose against the heparin still present, accounting for elapsed time, and administer slowly with coagulation monitoring; the label specifies up to 50 mg over 10 minutes.[23]

6. Ciraparantag (PER977) — Emerging Universal Reversal​

Synthetic small molecule designed as a universal reversal agent for DOACs (dabigatran, apixaban, rivaroxaban, edoxaban) and heparin. Investigational; not a routinely available reversal treatment.[2][18]

  • Binds anticoagulants through non-covalent hydrogen bonding and charge-charge interactions
  • Early data: rapid reversal of whole blood clotting time within 10–30 min of single IV dose
  • Urgency increased post-andexanet withdrawal; ciraparantag may fill the coverage gap if approved

7. Elective Surgery — Interruption, Bridging and Neuraxial Anesthesia​

In a DOAC-treated patient who needs urgent high-bleeding-risk surgery, assess the last dose, renal function, procedure risk, and a promptly available calibrated drug level; consider reversal when clinically significant drug effect remains.[38] For elective reconstructive surgery, plan interruption ahead; the full protocol lives on the Antithrombotic therapy page.

  • DOACs (PAUSE): in 3,007 patients with atrial fibrillation on apixaban, dabigatran or rivaroxaban, omitting apixaban, rivaroxaban, and dabigatran with CrCl ≥50 mL/min for 1 day before low-bleeding-risk procedures or 2 days before high-bleeding-risk procedures (dabigatran with CrCl 30–<50 mL/min was held 2 or 4 days, respectively), then resuming 1 day or 2–3 days after, without heparin bridging or drug-level testing, was associated with 30-day major bleeding of 0.90–1.85% and arterial thromboembolism of 0.16–0.60% across the three drug cohorts; major bleeding was 2.95–2.96% in the high-bleeding-risk apixaban and rivaroxaban subgroups.[31] Adjust for renal function per the workflow page.
  • Warfarin bridging (BRIDGE): in AF, omitting LMWH bridging was noninferior for arterial thromboembolism (0.4% versus 0.3%) and reduced major bleeding (1.3% versus 3.2%).[32] The 2022 ACCP perioperative guideline strongly recommends against heparin bridging in AF; bridging decisions for mechanical valves and recent VTE are separate.[30]
  • Neuraxial anesthesia: the enoxaparin label carries a boxed warning for spinal/epidural hematoma (risk rises with indwelling epidural catheters, concurrent NSAIDs, platelet inhibitors or other anticoagulants, and traumatic or repeated punctures), and states that optimal timing between the LMWH dose and neuraxial procedures is not known.[29] Use the ASRA fifth-edition intervals for each agent and dose level (which are deliberately conservative) when timing blocks, catheter removal and DOAC or LMWH resumption.[9]

Cross-Reference — What Lives on the Workflow Page​

TopicPage
Procedure-specific bleed-vs-thrombosis weighing in urologyWorkflow (Antithrombotic therapy)
DOAC hold timing before urologic surgeryWorkflow
Bridging decisions (mechanical valves, high-CHA₂DS₂-VASc)Workflow
Antiplatelet managementWorkflow
Antithrombin concentrate for heparin resistanceWorkflow
Drug-class pharmacology of reversal agentsThis article
Andexanet withdrawal and new FXa landscapeThis article

Practical Pearls​

  • Andexanet alfa is withdrawn from the US market. Off-label 4F-PCC regimens of 25–50 U/kg or fixed 2,000 U are options for FXa-inhibitor-associated life-threatening bleeding; select a regimen by bleeding site and local protocol.[3][4] Update institutional pre-op checklists and reversal algorithms.[1][2]
  • Idarucizumab is the specific agent for urgent dabigatran reversal. Give 5 g IV (2 × 2.5 g); median maximum dTT/ECT reversal was 100% in patients with prolonged baseline assays. Idarucizumab alone showed no procoagulant effect on endogenous thrombin potential, a surrogate assay. Coagulation parameters can rise again at 12–24 h; reassess if bleeding recurs.[14][15]
  • Give vitamin K concurrently with 4F-PCC for urgent warfarin reversal. For VKA-associated major bleeding, ACCP suggests 5–10 mg by slow IV injection (Grade 2C)[26]; NCCN cancer-associated VTE guidance specifies 10 mg IV for serious or life-threatening bleeding[6]; AHA/ASA guidance specifies 5–10 mg IV for VKA-related intracerebral hemorrhage[16]. In a 17-patient case review cited by the AHA/ASA guideline, INR rebounded 12–24 h later in two patients who received PCC without vitamin K.[16]
  • Protamine overdose causes bleeding. Avoid excess dosing and reassess coagulation rather than repeating a fixed ratio.[6][23]
  • Protamine only partly reverses LMWH anti-Xa activity. ASRA states that only the anti-IIa activity of LMWH is completely reversed, the anti-Xa activity is not fully neutralized, and both may return up to 3 hours after protamine reversal.[9] In vitro and animal studies show that protamine neutralizes the anti-IIa activity of LMWH but only a variable portion of its anti-Xa activity;[22] the Lovenox label specifies at most about 60% anti-Xa neutralization.[21][29]
  • Review prior protamine intolerance and exposure, including NPH insulin, before dosing. Fish allergy and prior vasectomy are label-listed possible risk factors.[23]
  • Reassess anticoagulation after bleeding control. In the single-arm ANNEXA-4 cohort, 26 of 34 patients with a thrombotic event had an event before restarting any anticoagulation.[10] RE-VERSE AD was also an uncontrolled cohort. Resume when medically safe after weighing recurrent bleeding and thrombosis.[10][14][15]
  • Ciraparantag remains investigational as a potential broad reversal agent; do not include it as an available rescue drug.[2][18]

See Also​

References​

1. US Food and Drug Administration. Update on the Safety of Andexxa. December 18, 2025: FDA considers the risks (including increased thromboembolic events) to outweigh the benefits; AstraZeneca ended US sales December 22, 2025.

2. Ng JX, Tan SC, Koh PL, Yap ES. "Anticoagulation stewardship program in the DOAC era." J Clin Med. 2026;15(7):2597. doi:10.3390/jcm15072597

3. Tomaselli GF, Mahaffey KW, Cuker A, et al. "2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants." J Am Coll Cardiol. 2020;76(5):594–622. doi:10.1016/j.jacc.2020.04.053

4. Joglar JA, Chung MK, et al; Writing Committee Members. "2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation." J Am Coll Cardiol. 2024;83(1):109–279. doi:10.1016/j.jacc.2023.08.017

5. Ruff IM, de Havenon A, Bergman DL, et al. "2024 AHA/ASA performance and quality measures for spontaneous intracerebral hemorrhage." Stroke. 2024;55(7):e199–e230. doi:10.1161/STR.0000000000000464

6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease. Updated 2025-11-06.

7. Frontera JA, Lewin JJ, Rabinstein AA, et al. "Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary." Crit Care Med. 2016;44(12):2251–2257. doi:10.1097/CCM.0000000000002057

8. Abraham NS, Barkun AN, Sauer BG, et al. "American College of Gastroenterology–Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period." Am J Gastroenterol. 2022;117(4):542–558. doi:10.14309/ajg.0000000000001627

9. Kopp SL, Vandermeulen E, McBane RD, et al. "Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (5th edition)." Reg Anesth Pain Med. 2025. doi:10.1136/rapm-2024-105766

10. Connolly SJ, Crowther M, Eikelboom JW, et al. "Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors." N Engl J Med. 2019;380(14):1326–1335. doi:10.1056/NEJMoa1814051

11. Connolly SJ, Sharma M, Cohen AT, et al. "Andexanet for factor Xa inhibitor–associated acute intracerebral hemorrhage." N Engl J Med. 2024;390(19):1745–1755. doi:10.1056/NEJMoa2313040

12. Panos NG, Jones GM, Cook AM, et al. "Reversal of factor Xa inhibitor-related intracranial hemorrhage: a multicenter, retrospective, observational study comparing the efficacy and safety of andexanet and prothrombin complex concentrates." Crit Care Med. 2025;53(6):e1202–e1213. doi:10.1097/CCM.0000000000006656

13. US Food and Drug Administration. ANDEXXA — prescribing information. Updated 2025-05-23.

14. US Food and Drug Administration. Praxbind (idarucizumab) — prescribing information. Updated 2024-01-23.

15. Pollack CV, Reilly PA, van Ryn J, et al. "Idarucizumab for dabigatran reversal — full cohort analysis." N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278

16. Greenberg SM, Ziai WC, Cordonnier C, et al. "2022 guideline for the management of patients with spontaneous intracerebral hemorrhage." Stroke. 2022;53(7):e282–e361. doi:10.1161/STR.0000000000000407

17. Puchstein D, Kork F, Schöchl H, Rayatdoost F, Grottke O. "3-factor versus 4-factor prothrombin complex concentrates for the reversal of vitamin K antagonist-associated coagulopathy: a systematic review and meta-analysis." Thromb Haemost. 2023;123(1):40–53. doi:10.1055/s-0042-1758653

18. van Es N, De Caterina R, Weitz JI. "Reversal agents for current and forthcoming direct oral anticoagulants." Eur Heart J. 2023;44(20):1795–1806. doi:10.1093/eurheartj/ehad123

19. Ageno W, Gallus AS, Wittkowsky A, et al. "Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines." Chest. 2012;141(2 Suppl):e44S–e88S. doi:10.1378/chest.11-2292

20. US Food and Drug Administration. Warfarin Sodium — prescribing information. Updated 2025-06-17.

21. Levy JH, Ghadimi K, Kizhakkedathu JN, Iba T. "What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives." J Thromb Haemost. 2023;21(7):1714–1723. doi:10.1016/j.jtha.2023.04.005

22. Garcia DA, Baglin TP, Weitz JI, Samama MM. "Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines." Chest. 2012;141(2 Suppl):e24S–e43S. doi:10.1378/chest.11-2291

23. Protamine sulfate prescribing information. DailyMed, updated April 29, 2025.

24. PRADAXA prescribing information. DailyMed; protein binding and dialysis limitations.

25. KCENTRA prescribing information. DailyMed; INR boundaries, vitamin K coadministration and contraindications.

26. Holbrook A, et al. Evidence-Based Management of Anticoagulant Therapy: CHEST 9th Edition guideline. 2012;141(2 Suppl):e152S–e184S. Section 9.1: elevated INR without bleeding. doi:10.1378/chest.11-2295

27. Steiner T, Poli S, Griebe M, et al. "Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial." Lancet Neurol. 2016;15(6):566–573. doi:10.1016/S1474-4422(16)00110-1

28. BALFAXAR prescribing information. DailyMed (Octapharma); indication, dosing table, weight cap and boxed warning.

29. LOVENOX (enoxaparin) prescribing information. DailyMed (Sanofi), revised May 2025; spinal/epidural hematoma boxed warning and protamine neutralization schedule (section 10, checked September 27, 2026).

30. Douketis JD, Spyropoulos AC, Murad MH, et al. "Executive summary: perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline." Chest. 2022;162(5):1127–1139. doi:10.1016/j.chest.2022.08.004

31. Douketis JD, Spyropoulos AC, Duncan J, et al. "Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant." JAMA Intern Med. 2019;179(11):1469–1478. doi:10.1001/jamainternmed.2019.2431

32. Douketis JD, Spyropoulos AC, Kaatz S, et al. "Perioperative bridging anticoagulation in patients with atrial fibrillation." N Engl J Med. 2015;373(9):823–833. doi:10.1056/NEJMoa1501035

33. Vallejo MC, Kennedy LS, Dengler B, et al. "Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and the Society of Critical Care Medicine." Neurocrit Care. Published online September 24, 2026. doi:10.1007/s12028-026-02601-4

34. Alembic Pharmaceuticals Limited. Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL) — prescribing information. Revised July 2025. DailyMed label.

35. US Food and Drug Administration. Cellular, Tissue, and Gene Therapies Advisory Committee November 21, 2024 Meeting Briefing Document: Andexxa (sBLA 125586/546). October 18, 2024, pp. 20–24. FDA PDF.

36. Halvorsen S, Mehilli J, Cassese S, et al. "2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery." Eur Heart J. 2022;43(39):3826–3924. doi:10.1093/eurheartj/ehac270

37. Takeda Pharmaceuticals America, Inc. FEIBA (anti-inhibitor coagulant complex) — prescribing information. Revised December 2024. DailyMed label.

38. Levy JH, Shaw JR, Castellucci LA, et al. "Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH." J Thromb Haemost. 2024;22(10):2889–2899. doi:10.1016/j.jtha.2024.07.009